Loading...
XNYS
CRL
Market cap10bUSD
Jul 09, Last price  
233.60USD
1D
4.30%
1Q
32.99%
Jan 2017
206.60%
IPO
967.64%
Name

Charles River Laboratories International Inc

Chart & Performance

D1W1MN
XNYS:CRL chart
P/E
P/S
2.80
EPS
Div Yield, %
Shrs. gr., 5y
-0.73%
Rev. gr., 5y
2.55%
Revenues
4.02b
-0.85%
1,297,662,0001,297,662,0001,363,302,0001,363,302,0001,681,432,0001,857,601,0001,857,601,0002,266,096,0002,266,096,0002,621,226,0002,621,226,0002,923,933,0002,923,933,0003,540,160,0003,540,160,0003,976,060,0004,129,409,0004,129,409,0004,049,989,0004,015,382,000
Net income
-144m
L
126,698,000126,698,000149,313,000149,313,000154,765,000123,355,000123,355,000226,373,000226,373,000252,019,000252,019,000364,304,000364,304,000390,982,000390,982,000486,226,000474,624,000474,624,00010,297,000-144,338,000
CFO
738m
+0.42%
251,051,000251,051,000286,358,000286,358,000298,319,000316,265,000316,265,000441,140,000441,140,000480,936,000480,936,000546,575,000546,575,000760,799,000760,799,000619,640,000683,898,000683,898,000734,577,000737,646,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
IPO date
Jun 23, 2000
Employees
20,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑122022‑122021‑122021‑122020‑122020‑122019‑122019‑122018‑122018‑122017‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT